β受体阻滞剂治疗婴儿血管瘤中国专家共识  

Chinese expert consensus on β-blockers for the treatment of infantile hemangioma

作　　者：无 马琳[5] 王华[6] 李丽[5] 汤建萍[7] 李萍[8] 无;Ma Lin;Wang Hua(Pediatric Dermatology Group,Chinese Society of Dermatology;Dermatology and Venereology Group,Chinese Pediatric Society,Chinese Medical Association;Pediatric Dermatology Committee,China Dermatologist Association;Pediatric Dermatology Rehabilitation Group,Dermatology Rehabilitation Committee,Chinese Association of Rehabilitation Medicine;不详)

机构地区：[1]中华医学会皮肤性病学分会儿童学组 [2]中华医学会儿科学分会皮肤性病学组 [3]中国医师协会皮肤科医师分会儿童皮肤病专业委员会 [4]中国康复医学会皮肤病康复专业委员会儿童皮肤病康复学组 [5]首都医科大学附属北京儿童医院皮肤科 [6]重庆医科大学附属儿童医院皮肤科 [7]湖南省儿童医院皮肤科 [8]深圳市儿童医院皮肤科

出　　处：《中华皮肤科杂志》2020年第7期493-500,共8页Chinese Journal of Dermatology

摘　　要：β受体阻滞剂是目前治疗婴儿血管瘤的一线药物,主要包括口服普萘洛尔和外用噻吗洛尔/卡替洛尔滴眼液。β受体阻滞剂药物选择及给药方式主要根据患儿年龄、瘤体部位、分型、分类及大小等因素综合决定。本共识对口服普萘洛尔的适应证及禁忌证、治疗起始时间及剂量、疗程与停药指征、用药期间注意事项和不良反应的监测及处理和特殊人群治疗剂量、疗程以及外用β受体阻滞剂适应证、应用具体方法等进行总结,希望为皮肤科及相关专业医生规范应用β受体阻滞剂治疗婴儿血管瘤提供参考依据。Currently,β-blockers are the first-line drugs for the treatment of infantile hemangioma,mainly including oral propranolol and topical timolol/carteolol eye drops.The selection and administration ofβ-blockers are mainly determined by factors such as children′s age,as well as tumor site,type,classification and size.This consensus summarizes indications and contraindications of oral propranolol,timing for initial therapy,start dose,start dose,course of treatment,indications for withdrawal,cautions during treatment,monitoring and management of adverse reactions,as well as therapeutic dose and course for special populations.The indications and specific administration methods of topicalβ-blockers are also described.It is hoped that this consensus provides a reference for dermatologists and relevant professional clinicians in proper application ofβ-blockers in the treatment of infantile hemangioma.

关 键 词：血管瘤 婴儿 肾上腺素能Β受体拮抗剂 普萘洛尔 噻吗洛尔 卡替洛尔 专家共识 

分 类 号：R732.2[医药卫生—肿瘤]